Abstract
The outcome of 114 patients with tumour-induced hypercalcaemia (TIH) treated between January 1992 and June 1993 with intravenous pamidronate (APD) was retrospectively analysed. The median overall survival was 55 days (range 3 days to > 21 months): 86 days if systemic anti-cancer therapy was available and only 35 days if not (P < 0.001). Survival was also significantly better for those who became normocalcaemic post APD (53 days vs 19 days, P < 0.001). There was no survival difference with respect to patient sex, age, tumour type, treatment of bone metastases with radiotherapy, initial calcium level, initial dose of APD or time from tumour diagnosis to first TIH. In those patients in whom systemic anti-cancer therapy is available, treatment with APD improves survival, but in all other patients the primary aim of treatment should be symptom control. This study confirms the dismal prognosis of TIH.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ling, P., A'Hern, R. & Hardy, J. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 72, 206–209 (1995). https://doi.org/10.1038/bjc.1995.304
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.304
This article is cited by
-
Metabolische Entgleisungen als paraneoplastische Syndrome
Der Internist (2018)
-
Tumorinduzierte Hyperkalzämie
Der Internist (2013)
-
Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence
Supportive Care in Cancer (2013)
-
Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis
Supportive Care in Cancer (2008)
-
Administration of bisphosphonate for hypercalcemia associated with oral cancer
Head & Face Medicine (2006)